Calithera Biosciences, Inc. (NASDAQ:CALA) management will conduct a conference call for 5th November 2020 at 5:00 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.calithera.com
Earnings Expectation
Calithera Biosciences, Inc. clinical-stage biopharmaceutical, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.31 per share. Looking ahead, the full year loss are expected at $ 1.29 per share.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology.
